What PGT Actually Is

Preimplantation genetic testing, or PGT, is a way of checking an embryo’s chromosomes or genes in the laboratory before it is transferred. During an IVF cycle, embryos are grown to the blastocyst stage, a few cells are safely sampled from the outer layer that will become the placenta, and the sample is analyzed. The embryo is then frozen while the result is returned, and only embryos that fit the plan are selected for transfer. The aim is straightforward: to reduce the chance of transferring an embryo with a genetic problem that would fail to implant, cause a miscarriage, or lead to a serious condition in a child.

It helps to separate PGT into three distinct tools, because they answer different questions. PGT-A checks the overall number of chromosomes and looks for aneuploidy—extra or missing chromosomes. PGT-M is used when one or both partners carry a specific single-gene disorder, such as cystic fibrosis or Huntington’s disease. PGT-SR applies when a parent carries a structural chromosome rearrangement, such as a balanced translocation. Most of the interest—and most of the confusion—centers on PGT-A, so much of this guide focuses there while noting where the other two apply.

What PGT-A Can Detect—and What It Cannot

PGT-A looks at chromosome number. A typical human embryo has 46 chromosomes, 23 from each parent. An embryo with 47 or 45 is described as aneuploid, and aneuploidy is a common reason that early pregnancies fail to implant or end in miscarriage. The frequency of aneuploid embryos rises with maternal age, which is why PGT-A is discussed more often in patients in their late thirties and forties.

What PGT-A does not do is check for every genetic condition. It does not diagnose single-gene disorders, which is the job of PGT-M. It does not guarantee a healthy baby or a live birth. It cannot assess every aspect of embryo development, and it does not correct a problem—it only reports what the sampled cells suggest. A result is a piece of information to inform a decision, not a verdict on an embryo’s potential. That boundary is worth repeating: PGT-A reduces certain risks; it does not eliminate risk.

Who Benefits Most from PGT-A

PGT-A is not automatically the right choice for every IVF patient. The situations in which it tends to add the most value include:

  • Advanced maternal age. As age rises, so does the proportion of embryos with chromosome errors. For patients in their late thirties and forties, PGT-A may help avoid transfers that are unlikely to succeed and shorten the time to a viable pregnancy.
  • Recurrent pregnancy loss. When two or more early losses have occurred, chromosome abnormalities in the embryo are a common underlying cause. Testing can clarify whether that is the pattern.
  • Repeated implantation failure. After several embryos fail to implant despite apparently good quality, PGT-A can help determine whether aneuploidy is the explanation.
  • A history of an aneuploid pregnancy or termination for a chromosome condition, which raises the question of whether a recurrence risk exists.

For a younger patient with a good ovarian reserve, a strong response to stimulation, and no history of loss, the added benefit may be smaller, and the decision is more finely balanced. This is a conversation to have with your physician using your own numbers and history—not a rule that applies to everyone. Age and reserve shape the calculation; our guide to AMH and ovarian reserve explains the inputs that feed it.

PGT-M and PGT-SR: When There Is a Known Condition

These two forms of testing are different from PGT-A because they are ordered for a specific, known reason in the family. PGT-M is relevant when one or both partners carry a pathogenic variant for a single-gene disorder, or when there is a strong family history of one. PGT-SR is relevant when a parent has a balanced translocation, inversion, or another structural rearrangement that can lead to embryos with unbalanced chromosomes. In both cases, the laboratory builds a test tailored to the family’s specific mutation or rearrangement before the cycle begins, which takes additional planning time.

Because these tests are condition-specific, genetic counseling is an essential part of the process. A counselor can explain the inheritance pattern, the chance that an embryo will be affected, and the options—including the possibility that no transferable embryo is available in a given cycle. This is a different conversation from routine IVF, and it should start well before stimulation.

How the Biopsy and Testing Process Works

The practical sequence is consistent. Embryos are created through IVF and cultured to the blastocyst stage, usually around day five or six. A specialist then performs a biopsy, removing a small number of cells from the trophectoderm—the outer cell layer that will form the placenta—while leaving the inner cell mass, which becomes the baby, undisturbed. The biopsied cells are sent to a genetics laboratory, and the embryos are vitrified (frozen) meanwhile.

Results typically return within one to two weeks, depending on the laboratory and the test type. Once they arrive, your physician reviews which embryos are suitable for transfer. A frozen embryo transfer is then scheduled in a later cycle, after the uterus has been prepared. If you are weighing how this fits with the broader treatment timeline, the comparison in IUI versus IVF and the timing questions in our fertility FAQs provide useful context.

Reading the Results: Euploid, Aneuploid, and Mosaic

A euploid embryo has the expected number of chromosomes. An aneuploid embryo has extra or missing chromosomes and is generally not recommended for transfer because of the low likelihood of a healthy outcome. A mosaic result is the ambiguous middle: the sampled cells show a mixture of normal and abnormal chromosomes. Mosaic results are difficult to interpret because the sampled cells may not perfectly represent the whole embryo, and their meaning depends on the specific chromosome involved and the proportion of abnormal cells.

This is exactly why results should be reviewed with your physician rather than read in isolation. A mosaic embryo is not automatically unusable, nor is it equivalent to a euploid one. The decision weighs the chance of implantation, the risk of miscarriage, the specific chromosomes involved, and how many other embryos are available. Guideline groups such as ASRM continue to refine how mosaic results should be counseled, reflecting how recently this technology has entered routine practice.

Success Rates: What PGT Does and Does Not Change

The most defensible statement about PGT-A is that it can improve the chance of pregnancy per transfer, particularly in older patients and in those with recurrent loss, by avoiding the transfer of embryos unlikely to succeed. What the evidence does not consistently show is an increase in the chance of a live birth per egg retrieval for every patient. If fewer embryos are available to transfer because some tested aneuploid, the per-transfer improvement may be offset.

This distinction—per transfer versus per retrieval—is one patients most often miss when reading clinic statistics. Ask exactly what a quoted figure measures, and for which age group. National registry data and published studies describe populations, not individuals, and no percentage can account for your specific reserve, diagnosis, and embryo quality. We deliberately avoid presenting a single clinic ‘success rate’ in these guides, because your own numbers are what matter. The fertility FAQs guide walks through how to interpret the figures you will encounter.

The Limits and the Hard Questions

PGT requires an IVF cycle with a blastocyst biopsy, which means it is not available to everyone and adds cost and time. There is also a possibility that no embryos are suitable for transfer in a given cycle, which can be emotionally difficult even when the testing has done exactly what it was meant to do. A biopsy is performed by experienced embryologists under carefully controlled conditions, but like any laboratory procedure it is not free of technical limitations.

There is also the question of what to do with the information. Some patients feel strongly that knowing is worthwhile; others prefer to avoid a result that could complicate an otherwise straightforward cycle. Both positions are reasonable. The role of the care team is to lay out the trade-offs honestly and support the decision that fits your values, not to push testing as an automatic add-on.

Questions Patients Ask Most

Does PGT damage the embryo?

The biopsy removes a few cells from the outer layer that becomes the placenta, not from the cells that become the baby. It is a well-established procedure performed by trained embryologists, and embryos are frozen afterward while results are pending. Like any laboratory step, it requires expertise, but it is not considered to harm the embryo’s ability to develop when done properly.

Is PGT the same as genetic carrier screening?

No. Carrier screening tests the parents to see whether they carry a gene variant that could be passed to a child. PGT tests the embryo. A couple may be offered carrier screening before IVF, and if a specific risk is found, PGT-M may then be considered. They are related but distinct steps.

Will PGT guarantee a healthy baby?

No. It reduces specific risks—primarily aneuploidy, or a known single-gene or structural condition—but it cannot screen for every condition, and a euploid result is not a guarantee of a live birth. Remaining risks are discussed in genetic counseling.

How long do results take?

Usually about one to two weeks, depending on the laboratory and the type of test. The embryos are frozen during that window, so the transfer is scheduled in a later cycle.

If all embryos test abnormal, is there another option?

Sometimes. The result may prompt a review of the stimulation protocol, a discussion about using donor eggs or sperm, or a decision about whether to pursue another retrieval. This is a situation where a candid conversation with your physician and a genetic counselor matters most.

Key Takeaways

  • PGT tests an embryo before transfer; PGT-A checks chromosome number, PGT-M checks a known single-gene condition, and PGT-SR checks structural rearrangements.
  • Aneuploidy becomes more common with maternal age, which is why PGT-A is discussed more often in patients in their late thirties and forties.
  • PGT-A can improve the chance of pregnancy per transfer, but evidence for a live-birth benefit per egg retrieval is less consistent.
  • A mosaic result is ambiguous and should be interpreted with your physician, not read as simply normal or abnormal.
  • PGT does not guarantee a healthy baby and cannot detect every genetic condition.
  • PGT-M and PGT-SR are ordered for a known family risk and require genetic counseling and advance planning.
  • Ask any clinic whether a quoted success figure is per transfer or per retrieval, and for which age group.

Taking the Next Step

Deciding whether to use PGT is a genuinely individual choice, and it works best when it starts with your own history rather than a general rule. A consultation can review your age, ovarian reserve, any history of pregnancy loss, and your family history, then weigh whether testing would change the plan in a way that matters to you. For a broader orientation to treatment options, see our fertility FAQs; to understand how testing fits into the treatment comparison, read IUI versus IVF. If you are considering preserving eggs before treatment, our guide to egg freezing may also be relevant.